Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian A Ference

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
European Heart Journal|October 12, 2017
Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists CollaborationBrian A Ference, Christopher P Cannon, Ulf Landmesser, et al.
JAMA Cardiology|October 24, 2019
Apolipoprotein B Particles and Cardiovascular Disease: A Narrative ReviewAllan D Sniderman, George Thanassoulis, Tamara Glavinovic, et al.
Atherosclerosis|June 12, 2020
Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?Zanfina Ademi, Richard Norman, Jing Pang, et al.
Plos Medicine|March 24, 2020
Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysisTom G Richardson, Eleanor Sanderson, Tom M Palmer, et al.
The American Journal of Cardiology|April 3, 2012
Role of non-high-density lipoprotein cholesterol in predicting cerebrovascular events in patients following myocardial infarctionNitin Mahajan, Brian A Ference, Natasha Arora, et al.
JAMA|September 28, 2016
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysisMichael G Silverman, Brian A Ference, Kyungah Im, et al.
Atherosclerosis|October 16, 2022
Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic strokeGian Marco De Marchis, Tolga D Dittrich, Rainer Malik, et al.
Circulation|September 19, 2019
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled TrialsNicholas A Marston, Robert P Giugliano, KyungAh Im, et al.
European Journal of Preventive Cardiology|June 23, 2021
Is the SMART risk prediction model ready for real-world implementation? A validation study in a routine care setting of approximately 380 000 individualsAilsa J McKay, Laura H Gunn, Brian A Ference, et al.
Journal of the American College of Cardiology|October 23, 2012
Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysisBrian A Ference, Wonsuk Yoo, Issa Alesh, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
European Heart Journal|October 12, 2017
Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists CollaborationBrian A Ference, Christopher P Cannon, Ulf Landmesser, et al.
JAMA Cardiology|October 24, 2019
Apolipoprotein B Particles and Cardiovascular Disease: A Narrative ReviewAllan D Sniderman, George Thanassoulis, Tamara Glavinovic, et al.
Atherosclerosis|June 12, 2020
Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?Zanfina Ademi, Richard Norman, Jing Pang, et al.
Plos Medicine|March 24, 2020
Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysisTom G Richardson, Eleanor Sanderson, Tom M Palmer, et al.
The American Journal of Cardiology|April 3, 2012
Role of non-high-density lipoprotein cholesterol in predicting cerebrovascular events in patients following myocardial infarctionNitin Mahajan, Brian A Ference, Natasha Arora, et al.
JAMA|September 28, 2016
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysisMichael G Silverman, Brian A Ference, Kyungah Im, et al.
Atherosclerosis|October 16, 2022
Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic strokeGian Marco De Marchis, Tolga D Dittrich, Rainer Malik, et al.
Circulation|September 19, 2019
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled TrialsNicholas A Marston, Robert P Giugliano, KyungAh Im, et al.
European Journal of Preventive Cardiology|June 23, 2021
Is the SMART risk prediction model ready for real-world implementation? A validation study in a routine care setting of approximately 380 000 individualsAilsa J McKay, Laura H Gunn, Brian A Ference, et al.
Journal of the American College of Cardiology|October 23, 2012
Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysisBrian A Ference, Wonsuk Yoo, Issa Alesh, et al.
Pageof 7